Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What's Gilead Getting From Kite For Nearly $12bn?

3d illustration of T cells or cancer cells

Related Content

Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing

Jun 08 2017

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

Dec 07 2016

Too Sick For CAR-T? Kite Reports Cerebral Edema Death

May 09 2017

Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review

Jul 13 2017

Kite First Off The Blocks For EU CAR-T Filing

Aug 01 2017

Related Companies

Gilead Sciences, Inc.

Kite Pharma, Inc.

Novartis AG

Bristol Myers Squibb Company

Additional Topics

Deals Business Strategies ImmunoOncology Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window